Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Arkin Capital
Herzliya Pituach / Herzliya, Israelarkin-capital.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Arkin Capital is a leading Israeli multi-stage asset manager with over $2 billion under management. Through its health-focused arms—especially "Arkin Bio Ventures" and "Arkin Bio Capital"—it invests globally in early-to-late stage biotech/pharma/digital health startups developing innovative therapies across modalities such as gene therapy, monoclonal antibodies, small molecules and more. Its investments target high unmet medical needs including oncology, immunology/autoimmunity, metabolic disease and CNS disorders. The group has backed multiple IPOs/M&A exits.
- Therapeutic areas
- OncologyMetabolic DisordersImmunologyNeurology
- Modalities
- Small moleculeMonoclonal antibodyGene therapyRNA therapyTargeted therapy
- Industry
- Investors
02
Partnerships
Phoenix GroupMigdal Insurance
Beyond the preview
Go deeper on Arkin Capital.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arkin Capital.